Preparation of buffy coat platelet hyperconcentrates treated with Mirasol® Pathogen Reduction Technology and stored in PAS

被引：0
|
作者：
de Korte, Dirk [1 ]
Marschner, S. [2 ]
Gouwerok, E. [3 ]
Vlaar, R.
Goodrich, R. [4 ]
机构：
[1] Sanquin Blood Bank Reg N W, Amsterdam, Netherlands
[2] Navigant Biotechnol, Lakewood, CO USA
[3] Sanquin Res, Amsterdam, Netherlands
[4] Navigant Biotechnol LLC, Lakewood, CO USA
来源：
TRANSFUSION | 2008年 / 48卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：154A / 154A
页数：1
相关论文
共 50 条
  • [41] Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System
    Abedi, Mohammad R.
    Doverud, Ann-Charlotte
    JOVE-JOURNAL OF VISUALIZED EXPERIMENTS, 2012, (70):
  • [42] Clinical Performance of Mirasol® Pathogen Reduction Technology Treated Platelets During Routine Use
    Antelo Caamano, M.
    Zalba Marcos, S.
    Ayape Puyales, L.
    Aranguren Azparren, A.
    Aranburu, E.
    Marschner, S.
    Cardoso, M.
    TRANSFUSION, 2011, 51 : 58A - 59A
  • [43] QUALITY CONTROL OF FIBRINOGEN CONCENTRATE FROM PLASMA TREATED IN MIRASOL® PATHOGEN REDUCTION TECHNOLOGY
    Lachert, E.
    Kubis, J.
    Antoniewicz-Papis, J.
    Rosiek, A.
    Potocka, E.
    Poglod, R.
    Letowska, M.
    VOX SANGUINIS, 2013, 105 : 154 - 154
  • [44] IN VITRO CELL QUALITY OF ATREUS® 3C DERIVED PLATELET CONCENTRATES TREATED WITH THE MIRASOL® PATHOGEN REDUCTION TECHNOLOGY SYSTEM
    Maia, S.
    Ramoa, A.
    Pacheco, R.
    Ruivo, I
    van Waeg, G.
    VOX SANGUINIS, 2010, 99 : 245 - 245
  • [45] Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates
    Perez-Pujol, S
    Tonda, R
    Lozano, M
    Fuste, B
    Lopez-Vilchez, I
    Galan, AM
    Li, J
    Goodrich, R
    Escolar, G
    TRANSFUSION, 2005, 45 (06) : 911 - 919
  • [46] Analysis of Plasma Treated with Mirasol® Pathogen Reduction Technology and Stored up to Two Years at Variable Temperatures (-18°C AND-30°C)
    Miklauz, M. M.
    Larrea, L.
    Scheel, E.
    Smith, J. W.
    Marschner, S.
    Goodrich, R. P.
    TRANSFUSION, 2011, 51 : 44A - 45A
  • [47] ANNEXIN V BINDING DURING STORAGE OF PLATELET CONCENTRATE FROM BUFFY COAT, AFTER PATHOGEN REDUCTION TREATMENTS
    Castrillo Fernandez, A.
    Arcas Otero, C.
    Rodriguez Calvo, M., I
    VOX SANGUINIS, 2012, 103 : 138 - 139
  • [48] THE EFFECT OF PATHOGEN REDUCTION TECHNOLOGY (MIRASOL) ON THE INFECTIVITY OF DENUGE VIRUSES
    Faddy, H.
    Fryk, J.
    Young, P.
    Watterson, D.
    Goodrich, R.
    Marks, D.
    VOX SANGUINIS, 2012, 103 : 191 - 191
  • [49] Therapeutic efficacy of pooled buffy-coat platelet components prepared and stored with a platelet additive solution
    van Rhenen, DJ
    Gulliksson, H
    Cazenave, JP
    Pamphilon, D
    Davis, K
    Flament, J
    Corash, L
    TRANSFUSION MEDICINE, 2004, 14 (04) : 289 - 295
  • [50] Bioactive substances in buffy-coat-derived platelet pools stored in platelet-additive solutions
    Edvardsen, L
    Taaning, E
    Mynster, T
    Hvolris, J
    Drachman, O
    Nielsen, HJ
    BRITISH JOURNAL OF HAEMATOLOGY, 1998, 103 (02) : 445 - 448
12345